Drug firm Zydus Cadila today said it has received the final clearance from the US health regulator to market Zolmitriptan tablets, indicated for migraine patients.
The approval from the United States Food and Drug Administration (USFDA) is for marketing the tablets in the strengths of 2.5 mg and 5 mg in the US, Zydus Cadila said in a statement.
The product will be manufactured at the group's facility at Moraiya in Ahmedabad, it added.
Zolmitriptan tablets are indicated for treatment of migraine. It helps in relieving headache, pain, and other migraine symptoms, it said.
The group now has 203 approvals and has so far filed over 330 abbreviated new drug applications (ANDAs), it added.
Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 366.80 per scrip on BSE, down 1.27 per cent from the previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
